Study on the incidence rate of cervical cancer on 1.122 women aged from 15 to 69 years old were interviewed and had a gynaecological examination in an urban district of HoChiMinh city. HPV DNA detection was performed using a GP5+/6+ primer-mediated PCR enzyme immunoassay. IgG antibodies against herpes simplex virus (HSV-2) were determined in blood samples using an ELISA assay. The results showed that: HPV DNA was detected among 10.9% of women in HoChiMinh city. 28 different HPV types were detected, the most common being HPV 16 (in 14 single and 18 multiple infections), followed by HPV 58, 18 and 56. A peak of HPV DNA detection in women below age 25 was found. Major risk factors for HPV DNA detection in the multivariate analyses were: indicators of sexual habits, most notably the presence of HSV-2 antibodies, nulliparity and the current use of oral contraceptives
Human papillomavirus 16 ; Human papillomavirus 18 ; epidemiology ; women

OBJECTIVETo analyze the infection condition of human papillomavirus (HPV) type 16 and 18 in the squamous cells and columnar cells of patients with common anorecatal lesions.

METHODSInfections of HPV type 16 and 18 were determined with real-time fluorescent quantitative PCR in the wax-embedded surgical specimen of 805 patients with common anorectal diseases.

RESULTSThe overall infection rate among 805 patients with anorecatal lesions was 66.1% (532/805). The infection rate was 82.6% (95/115) in patients with mixed hemorrhoids, 76.5% (88/115) in anal papillary fibromas, 74.8% (86/115) in internal hemorrhoids, 72.2% (83/115) in fistulas, 69.6% (80/115) in external hemorrhoids, 47.8% (55/115) in anal perianal abscesses, and 39.1% (45/115) in anal fissures.

CONCLUSIONInfection rate of HPV type 16, 18 in common anorectal lesions is high.

OBJECTIVE: The purpose of this study was to assess the role of HPV 16 and 18 in adenocarcinoma in situ(ACIS) of the uterine cervix. METHODS: Seventeen cases of primary cervical adenocarcinoma in situ were analyzed for HPV DNA by polymerase chain reaction. HPV 16 and 18 DNA extracted from formalin-fixed, paraffin-embedded histologic tissue sections by polymerase chain reaction. RESULTS: 35.3% and 23.5% of ACIS were positive for HPV 16 and HPV 18 DNA, respectively. From the normal tissue, 11.8% were positive for HPV 16. Human papillomavirus positive patients were younger than negative patients but statistically insignificant(mean age 42.1 vs 51.7 years). CONCLUSIONS: These results show that HPV type 16 and 18 were closely related to etiology of the ACIS of the uterine cervix.
Adenocarcinoma* ; Cervix Uteri* ; DNA ; Female ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans* ; Papilloma* ; Polymerase Chain Reaction

The necessary role of genital infection by specific types of human papillomavirus (HPV) in cervical cancer development provides an opportunity to reduce the risk of cervical cancer, a second leading cancer in women, through prophylactic vaccination. Two types of vaccines targeting HPV 16 and 18 which are responsible for about 70% of all cervical cancer worldwide have been developed: a quadrivalent vaccine (Gardasil?) and a bivalent vaccine (Cervarix?). Gardasil also targets HPV 6 and 11 causing 90% of genital wart. Both two vaccines contain virus-like particles composed of L1 protein of viral capsid and do not exert infectivity. HPV vaccines were highly effective in preventing persistent infection by vaccine specific type HPV in young women who have not been previously exposed to them. Randomized double-blind placebo-controlled clinical trials have provided evidence that HPV vaccines have high efficacy against cervical precancerous lesion in young women irrespective of baseline HPV infection status. However, HPV vaccines neither treat existing HPV infections nor provide protection against all types of HPV related with cervical cancer. Therefore, even vaccinated females should take cervical cancer screening as recommended. Gardasil has been tested mainly in 9~26 years old females and Cervarix in 15~25 years old. Current recommendation for vaccination age is 9~26 years for Gardasil and 10~25 years for Cervarix, considering sexual debut and previous clinical trials. There are plenty of remaining issues regarding HPV vaccination such as vaccine efficacy in older women and in males, cost-effectiveness, duration of protection, cross-protection, potential replacement infection, and vaccine compatibility.
Cancer Vaccines ; Capsid ; Condylomata Acuminata ; Female ; Human papillomavirus 16 ; Human papillomavirus 18 ; Human papillomavirus 6 ; Humans ; Male ; Mass Screening ; Papillomavirus Vaccines ; Uterine Cervical Neoplasms ; Vaccination ; Vaccines ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

BACKGROUND: Human papillomavirus (HPV) is a small double-stranded DNA virus. Of HPV, type 16 and 18 are associated with high risk in the development of cervical cancer. In order to evaluate HPV infections, several HPV typing and detection methods have been developed. The aim of this study was to compare the detection rates of HPV 16 and 18 by polymerase chain reaction (PCR), in situ hybridization(ISH), and PCR in situ in uterine cervical cancers. METHODS: PCR, ISH and PCR in situ were performed for the detection of HPV DNA in fifty-one formalin fixed, paraffin embedded blocks of uterine cervical cancer tissues. Twenty uterine cervical specimens from patients with uterine myomas were used as controls. RESULTS: The detection rates of HPV 16 and HPV 18 in cervical cancers were 56.9% (29/51) and 45.1% (23/51) by PCR, 9.8% (5/51) and 5.9% (3/51) by ISH, 17.6% (9/51) and 11.8% (6/51) by PCR in situ, respectively. In control group, the detection rate of HPV 16 and 18 by PCR were 10% (2/20) and 5% (1/20), but HPV was not detected by both ISH and PCR in situ. CONCLUSION: PCR was the most sensitive method for the detection of HPV. However, PCR in situ was more informative fort the specific detection and cell localization of HPV DNA.
DNA ; Formaldehyde ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans* ; In Situ Hybridization* ; Leiomyoma ; Paraffin ; Polymerase Chain Reaction* ; Uterine Cervical Neoplasms*

OBJECTIVE: Previous studies were showed that adenoassocited virus (AAV) infection was had negative effects on human papillomavirus (HPV) infection and that the cervical cancer cell growth is inhibited by AAV infection. We detected of AAV 2 and high-risk HPV infection and researched correlation with AAV 2 and HPV in cervical cell. METHODS: Cell of normal cervix (49 persons), infected HPV cervix (45 persons), cervical intraepithelial neoplasm (CIN) I (31 persons), II (20 persons), III (35 persons), and invasive cancer (30 persons) were investigated by PCR using AAV-2 and HPV type 16 and 18 specific primers. RESULTS: AAV 2 was detected in 8 out of 49 normal cervix (16.3%), 2 out of 45 infected HPV cervix (4.4%), 3 out of 31 CIN I (9.7%), 4 out of 20 CIN II (20%), 8 out of 35 CIN III (22.8%), and 3 out of 30 invasive cervical cancer cases (30%). However, HPV 16 was detected in 5 out of 49 normal cervix (10.2%), 20 out of 45 infected HPV cervix (44.4%), 13 out of 31 CIN I (42%), 11 out of 20 CIN II (55%), 19 out of 35 CIN III (54.3%), and 21 out of 30 invasive cervical cancer cases (70%). HPV 18 was detected in 6 out of 49 normal cervix (12.2%), 18 out of 45 infected HPV cervix (40%), 16 out of 31 CIN I (51.6%), 10 out of 20 CIN II (50%), 22 out of 35 CIN III (62.8%), and 13 out of 30 invasive cervical cancer cases (43.3%). CONCLUSION: AAV 2 was detected in normal and infected HPV cervix, CIN (I, II, III) and invasive cervical cancer. As compared to normal, CIN I and CIN II, suggesting significant correlation between AAV 2 and HPV type 16. Further, researches continue to be done relationship to AAV 2 and HPV infection in cervix.
Cervical Intraepithelial Neoplasia ; Cervix Uteri* ; Female ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans* ; Polymerase Chain Reaction ; Uterine Cervical Neoplasms

OBJECTIVE: To validate the efficacy of Seeplex HPV4A ACE for the detection of high-risk (HR) human papillomavirus (HPV) and HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples. METHODS: Besides liquid-based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen's kappa statistic, and a receiver operating characteristic curve. RESULTS: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3%, kappa=0.767 and 81.7%, kappa=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 test (89.5%, kappa=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4% vs. 84.5% and 73.4%, vs. 72.7%, respectively, when those higher than low-grade squamous intraepithelial lesions were regarded as abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7% vs. 24.6% by HPV4A ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, relatively). CONCLUSION: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and for genotyping of HPV 16 and 18.
Cervical Intraepithelial Neoplasia ; Chimera ; Genotype ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans ; Polymerase Chain Reaction ; ROC Curve ; Sensitivity and Specificity

OBJECTIVE: The study assessed the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Korean women aged 15-25 years. METHODS: Phase IIIB, double-blind, randomised (2:1), multi-centre trial was conducted in Korea from June 2007 to March 2008. The study enrolled 225 women in the HPV (N=149) and placebo (N=76) groups who received three doses of HPV-16/18 AS04-adjuvanted vaccine or placebo (aluminium hydroxide) administered intramuscularly at 0, 1, and 6 months and were followed until one month post-dose 3. Serum samples were collected pre-vaccination and one month post-dose 3. Safety and reactogenicity data were collected throughout. RESULTS: In this trial, 208 women completed the study (141 in HPV group; 67 in placebo group). At month 7, all initially seronegative women had seroconverted for HPV-16 and HPV-18 antibodies with anti-HPV-16 and anti-HPV-18 geometric mean titres of 9,351.4 El.U/mL (95% CI, 8,145.5 to 10,735.8) and 4204.1 El.U/mL (95% CI, 3,626.5 to 4,873.6), respectively. Initially seropositive women showed similar increase in geometric mean titre levels. Compliance to the three dose vaccination course was 95.3% in HPV and 89.5% in placebo group. Solicited local (pain) and general (fatigue, myalgia or headache) symptoms were commonly reported in both groups. Three serious adverse events were reported (two in HPV group; one in placebo group), all unrelated to vaccination by the investigator; all recovered. CONCLUSION: The HPV-16/18 AS04-adjuvanted vaccine was highly immunogenic with a clinically acceptable safety profile in Korean women. This study was in line with previous global studies in Europe, North America, and Brazil. (ClinicalTrials.gov number, NCT 00485732.)
Aged ; Antibodies ; Brazil ; Compliance ; Europe ; Female ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans ; Korea ; North America ; Uterine Cervical Neoplasms ; Vaccination

To investigate the role of human pepillomavirus(HPV) infection on DNA content of cervical cancers, thirty-seven cases af ceryical squamous carcinoma were studied with the method of flow cytometry for deoxyribonucleic acid(DMA) content and Southern blot hybridizalion for typing of HPV type 1.6 or type 18 DWA in cornbination with other elinical pnrameters. There were 18 dipleid cases(48.6%) and 19 aneuploid(51.4%). The mean age of the patients with diplaid and aneuploid tumars was 51.6 years and 53.6 years, respectively, No significant age difference was found between diploid and aneuploid groups. Six of 13(46.2%) carcinnma in eiiu and 13 of 24(54.2%) invasive cervical carcinoma were aneuploid, and t,he proportinn of aneuploid tumors was not significantly different between the two groups. Six of 10 tumors(60.0%) in stage I, 5 of 11 tumors(45.5%) in stage II, 2 of 3 tumors(66.7%) in stage III were aneuploid. The frequency was not significantly different according to the clinical stage, Aneuploidy was present in 50.0% of HPV 16 positive lesion, 66.7% of HPV 18 positive lesion, and 41.7% of HPV 16 and 18 negative lesion. There was no statistically difference in the incidenee of aneuploidy when all HPV lesions were compared. Of 25 patients with HFV 16 or l8 positive lesion, aneuploidy was demonstrated in the specimen of four of eight patients with careinoma in situ and nine of 17 with invasive cervical carcinoma. In suromary, we found thst the ineidere of DNA aneuploidy was somewhat higher when HPV 18 positive lesion was compared to HPV 16 and 18 negative lesion but the difference was not statistically significant.
Aneuploidy ; Blotting, Southern ; Carcinoma, Squamous Cell ; Diploidy ; DNA* ; Flow Cytometry ; Human papillomavirus 16 ; Human papillomavirus 18 ; Humans ; Humans*

OBJECTIVE: This study evaluates the effect of the specific human papillomavirus (HPV) genotype as a prognostic factor in stage I-IIA cervical cancer patients following primary surgical treatment. METHODS: The medical records of 116 cervical cancer patients treated with primary surgical treatment were reviewed. The HPV genotypes were categorized into following groups: negative and unclassified, HPV 16, HPV 18, and other high risk (HPV 31, 33, 35, 45, 51, 52, 56, and 58). RESULTS: Among the HPV genotypes, HPV 16 predominated (40.52%), followed by intermediate risk and unclassified (25%), HPV 18, 45, and 56 (17.24%) and negative (17.24%). In univariate analysis, HPV genotypes (P=0.03), parametrial spread (P=0.02), depth of invasion (DOI) (P<0.01) and lymph-vascular space invasion (P=0.02) were significantly associated with progression free survival (PFS). In multivariate analysis, HPV 18 (hazard ratio [HR], 5.2; 95% confidence interval [CI], 1.29 to 20.90; P=0.02) and > or =one half of DOI (HR, 5.4; 95% CI, 1.08 to 27.31; P=0.04) were significantly associated with PFS. HPV genotypes are not significantly associated with overall survival. CONCLUSION: HPV 18 was a poor prognostic factor for the PFS in stage I-IIA cervical cancer patients following primary surgical treatment. Careful long-term observation and regular exams are recommended for cervical cancer patients with HPV 18 compared to those with other HPV genotypes.
Disease-Free Survival ; Genotype ; Human papillomavirus 16 ; Human papillomavirus 18* ; Humans ; Medical Records ; Multivariate Analysis ; Prognosis ; Uterine Cervical Neoplasms*